Shihong Sheng

2.1k total citations · 2 hit papers
28 papers, 1.5k citations indexed

About

Shihong Sheng is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Shihong Sheng has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 18 papers in Immunology and 16 papers in Hematology. Recurrent topics in Shihong Sheng's work include Psoriasis: Treatment and Pathogenesis (16 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Spondyloarthritis Studies and Treatments (13 papers). Shihong Sheng is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Spondyloarthritis Studies and Treatments (13 papers). Shihong Sheng collaborates with scholars based in United States, United Kingdom and Canada. Shihong Sheng's co-authors include Yanli Zhuang, Alexa P. Kollmeier, Xie L. Xu, Elizabeth C. Hsia, Prasheen Agarwal, Philip J. Mease, Benjamin Hsu, Iain B. McInnes, Proton Rahman and Désirée van der Heijde and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Shihong Sheng

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

2020 242 citations Philip J. Mease, Proton Rahman et al. The Lancet profile →
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

2020 233 citations Atul Deodhar, Philip Helliwell et al. The Lancet profile →

Peers

Countries citing papers authored by Shihong Sheng

Since Specialization

Citations

This map shows the geographic impact of Shihong Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shihong Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shihong Sheng more than expected).

Fields of papers citing papers by Shihong Sheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shihong Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shihong Sheng. The network helps show where Shihong Sheng may publish in the future.

Co-authorship network of co-authors of Shihong Sheng

This figure shows the co-authorship network connecting the top 25 collaborators of Shihong Sheng. A scholar is included among the top collaborators of Shihong Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shihong Sheng. Shihong Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis 2024 ·Clinical Rheumatology ·Proton Rahman, Iain B. McInnes, Atul Deodhar, Georg Schett, Phillip J. Mease, M. Shawi, J. Daniel, Jonathan Sherlock, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Christopher T. Ritchlin, Dennis McGonagle	0
2	Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies 2023 ·ACR Open Rheumatology ·Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, M. Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease	4
3	Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study 2023 ·ACR Open Rheumatology ·Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, (unknown), M. Shawi, (unknown), Shihong Sheng, Philip Helliwell	9
4	Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis 2023 ·RMD Open ·Alice B. Gottlieb, Iain B. McInnes, Proton Rahman, Alexa P. Kollmeier, Xie L. Xu, (unknown), Shihong Sheng, M. Shawi, Soumya D. Chakravarty, F. Lavie, Philip J. Mease	5
5	Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis 2023 ·The Journal of Rheumatology ·Proton Rahman, Wolf‐Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, (unknown), M. Shawi, Yanli Wang, Shihong Sheng, Alexa P. Kollmeier, Elke Theander, (unknown), (unknown), (unknown), Laura C. Coates	12
6	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies 2022 ·RMD Open ·Christopher T. Ritchlin, Philip J. Mease, Wolf‐Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, M. Shawi, (unknown), Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar	18
7	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis 2022 ·Lara D. Veeken ·Laura C. Coates, Christopher T. Ritchlin, Laure Gossec, Philip Helliwell, Proton Rahman, Alexa P. Kollmeier, Xie L. Xu, M. Shawi, Chetan S. Karyekar, (unknown), W. Noël, Shihong Sheng, Yanli Wang, Stephen Xu, Philip J. Mease	11
8	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study 2022 ·Patient ·Ana‐Maria Orbai, Laura C. Coates, Atul Deodhar, Philip Helliwell, Christopher T. Ritchlin, (unknown), Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, (unknown), Yan Liu, Chenglong Han	3
9	S716 Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study 2022 ·The American Journal of Gastroenterology ·Brian G. Feagan, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Shihong Sheng, Jewel Johanns, Julián Panés	0
10	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis 2021 ·Arthritis & Rheumatology ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, (unknown), Shihong Sheng, M. Shawi, Soumya D. Chakravarty, Désirée van der Heijde, Philip J. Mease	66
11	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced 2021 ·RMD Open ·Christopher T. Ritchlin, Philip Helliwell, Wolf‐Henning Boehncke, Enrique R. Soriano, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, (unknown), Ramanand A. Subramanian, Xie L. Xu, Qing Zuraw, Shihong Sheng, (unknown), Prasheen Agarwal, Bei Zhou, Yanli Zhuang, M. Shawi, Chetan S. Karyekar, Atul Deodhar	50
12	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies 2021 ·The Lancet Rheumatology ·Philip J. Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Xenofon Baraliakos, Soumya D. Chakravarty, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Kristen Sweet, M. Shawi, Chetan S. Karyekar, Atul Deodhar, Désirée van der Heijde	61
13	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis 2021 ·The Journal of Rheumatology ·Proton Rahman, Christopher T. Ritchlin, Philip Helliwell, Wolf‐Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, M. Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, (unknown), Yanli Zhuang, Iain B. McInnes	19
14	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis 2020 ·Arthritis & Rheumatology ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Xie L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, Shihong Sheng, (unknown), Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Philip J. Mease	56
15	Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial breakdown → 2020 ·The Lancet ·Atul Deodhar, Philip Helliwell, Wolf‐Henning Boehncke, Alexa P. Kollmeier, Elizabeth C. Hsia, Ramanand A. Subramanian, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T. Ritchlin	233
16	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial breakdown → 2020 ·The Lancet ·Philip J. Mease, Proton Rahman, Alice B. Gottlieb, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, B. Zhou, Yanli Zhuang, Désirée van der Heijde, Iain B. McInnes	242
17	Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study 2017 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Carter Thorne, George Karpouzas, Shihong Sheng, Weichun Xu, Ravi Rao, Kaiyin Fei, Benjamin Hsu, Paul P. Tak	55
18	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy 2014 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Michael E. Weinblatt, Shihong Sheng, Yanli Zhuang, Benjamin Hsu	131
19	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial 2013 ·Annals of the Rheumatic Diseases ·Michael E. Weinblatt, René Westhovens, Alan M. Mendelsohn, Lilianne Kim, Kim Hung Lo, Shihong Sheng, Lenore Noonan, Jiandong Lu, Zhenhua Xu, Jocelyn H. Leu, Daniel Baker, Clifton O. Bingham	33
20	Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia 2006 ·Cancer ·Stefan Faderl, R. Kanti, John G. Gribben, John C. Byrd, Ian W. Flinn, Susan O’Brien, Shihong Sheng, Dixie‐Lee Esseltine, Michael J. Keating	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact